Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy-Reference-Cited by-同舟云学术

Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy

Published:2023-05-09 Issue:8 Volume:60 Page:1099-1108
ISSN:1432-5233
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Zaitoon Hussein,Lubetzky Ronit,Amir Achiya Z.,Moran-Lev Hadar,Sagi Liora,Yacobi-Bach Michal,Borger Ophir,Chorna Efrat,Lebenthal Yael,Brener Avivit^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00592-023-02109-9.pdf

Reference45 articles.

1. Jebeile H, Kelly AS, O’Malley G, Baur LA (2022) Obesity in children and adolescents: epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol 10:351–365. https://doi.org/10.1016/S2213-8587(22)00047-X

2. Serra-Juhé C, Martos-Moreno G, Bou de Pieri F et al (2020) Heterozygous rare genetic variants in non-syndromic early-onset obesity. Int J Obes (Lond) 44:830–841. https://doi.org/10.1038/S41366-019-0357-5

3. Loos RJF, Yeo GSH (2022) The genetics of obesity: from discovery to biology. Nat Rev Genet 23:120–133. https://doi.org/10.1038/S41576-021-00414-Z

4. Thaker VV (2017) Genetic and epigenetic causes of obesity. Adolesc Med State Art Rev 28:379–405. https://doi.org/10.1542/9781581109405-genetic

5. Farooqi IS (2021) Monogenic human obesity syndromes. Handb Clin Neurol 181:301–310. https://doi.org/10.1016/B978-0-12-820683-6.00022-1

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity;Current Opinion in Pediatrics;2024-06-14

2. HNF1A induces glioblastoma by upregulating EPS8 and activating PI3K/AKT signaling pathway;Biochemical Pharmacology;2024-05

3. Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report;Hormone Research in Paediatrics;2024-02-23